16.41 KWD
Mirvaso Topical Gel is a prescription treatment designed to reduce persistent facial redness (erythema) caused by rosacea in adults. Its active ingredient, brimonidine tartrate, is an alpha2-adrenergic receptor agonist that works by narrowing dilated blood vessels in the skin, leading to a visible reduction in redness.
Brimonidine tartrate (3.3 mg per gram): Acts to constrict blood vessels in the facial skin, effectively reducing excessive blood flow and redness associated with rosacea.
Other ingredients: Glycerol, propylene glycol, carbomer, phenoxyethanol, methyl hydroxybenzoate (E218), titanium dioxide, sodium hydroxide, purified water. These help moisturize, stabilize, and preserve the gel.
Rapidly reduces facial redness due to rosacea
Results often visible within 30 minutes of application
Compatible with other rosacea treatments and cosmetics
Convenient once-daily application
Apply a small, pea-sized amount to the forehead, chin, nose, and each cheek once daily.
Start with less than the maximum dose for the first week; increase gradually based on tolerability and response.
Wash hands after application and avoid contact with eyes, lips, or inside the nose.
Do not exceed the maximum daily dose (1 g per day).
Adults with persistent facial redness due to rosacea
Not suitable for children under 18 years
Noticeable reduction in facial redness, often within 30 minutes
Improved comfort and appearance with regular use
Do not use if allergic to brimonidine or any other ingredients in the gel
Not recommended for children under 18 years
Avoid if taking certain medications for depression or Parkinson’s disease
Consult your doctor if you have severe heart, kidney, or liver problems, or certain medical conditions (such as Sjögren’s syndrome)
Dryness, irritation, or burning at the application site
Flushing, itching, or mild discomfort
Rarely, dizziness or a drop in blood pressure
Active ingredient: Brimonidine tartrate
Form: Topical gel
Pack size: 30 grams